



14 March 2023

**LungLife AI, Inc.**  
(the “Company” or “LungLife”)

**Appointment of Joint Broker**

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, announces the appointment of Goodbody as the Company's Joint Broker with immediate effect.

Investec Bank plc remains Nominated Adviser and Joint Broker to the Company.

**For further information please contact:**

**LungLife AI, Inc.**

Paul Pagano, CEO  
David Anderson, CFO

[www.lunglifeai.com](http://www.lunglifeai.com)

Via Walbrook PR

**Investec Bank plc (Nominated Adviser & Joint Broker)**

Virginia Bull / Cameron MacRitchie / Lydia Zychowska

Tel: +44 (0)20 7597 5970

**Goodbody (Joint Broker)**

Tom Nicholson / Stephen Kane

Tel: +44 (0) 20 3841 6202 / +353 (1) 667 0420

**Walbrook PR Limited**

Stephanie Cuthbert / Alice Woodings / Phillip Marriage

Tel: +44 (0)20 7933 8780 or [LungLifeAI@walbrookpr.com](mailto:LungLifeAI@walbrookpr.com)

Mob: 07980 541 893 / 07407 804 654 / 07867 984 082

**About LungLife**

LungLife AI is a developer of clinical diagnostic solutions designed to make a significant impact in the early detection of lung cancer, the deadliest cancer globally. Using a minimally invasive blood draw, the Company's LungLB® test is designed to deliver additional information to clinicians who are evaluating indeterminate lung nodules. For more information visit [www.lunglifeai.com](http://www.lunglifeai.com)

Our Purpose is to be a driving force in the early detection to lung cancer. Our Vision is to invert the 20:80 ratio such that in years to come at least 80% of lung cancer is detected early.